Arcus Hunting, LLC, USA, the maker of Tink’s and Dead Down Wind hunting scents, announced a new licensing partnership to ...

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ongoing ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Simon Arcus has resigned as the chief executive of the Wellington Chamber of Commerce and parent organisation Business ...

(RTTNews) - Arcus Biosciences, Inc. (RCUS) Thursday said that its quemliclustat was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic ...

Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer PRISM-1, the ongoing registrational, Phase 3 study evaluating quemliclustat plus chemotherapy as a first ...

About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer.